SGMO vs. EBS, RIGL, CDXS, XOMA, IRWD, VSTM, VNDA, LXRX, ACHV, and AGEN
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Codexis (CDXS), XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), and Agenus (AGEN). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs.
Emergent BioSolutions (NYSE:EBS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
Sangamo Therapeutics received 29 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.77% of users gave Emergent BioSolutions an outperform vote while only 62.76% of users gave Sangamo Therapeutics an outperform vote.
In the previous week, Emergent BioSolutions had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Emergent BioSolutions and 1 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 1.02 beat Emergent BioSolutions' score of 0.20 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.
Emergent BioSolutions presently has a consensus price target of $14.33, indicating a potential upside of 82.71%. Sangamo Therapeutics has a consensus price target of $5.17, indicating a potential upside of 361.31%. Given Sangamo Therapeutics' higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Emergent BioSolutions.
Sangamo Therapeutics has lower revenue, but higher earnings than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Emergent BioSolutions has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
78.4% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 1.2% of Emergent BioSolutions shares are owned by insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Emergent BioSolutions has a net margin of -18.55% compared to Sangamo Therapeutics' net margin of -257.87%. Emergent BioSolutions' return on equity of -9.91% beat Sangamo Therapeutics' return on equity.
Summary
Emergent BioSolutions and Sangamo Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SGMO) was last updated on 2/21/2025 by MarketBeat.com Staff
